Corvus Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CEORichard A. Miller
CEORichard A. Miller
Employees31
Employees31
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2014
Founded2014
Employees31
Employees31
CRVS Key Statistics
Market cap655.71M
Market cap655.71M
Price-Earnings ratio-16.40
Price-Earnings ratio-16.40
Dividend yield—
Dividend yield—
Average volume1.15M
Average volume1.15M
High today$8.98
High today$8.98
Low today$7.81
Low today$7.81
Open price$7.89
Open price$7.89
Volume1.16M
Volume1.16M
52 Week high$9.55
52 Week high$9.55
52 Week low$2.54
52 Week low$2.54
Stock Snapshot
With a market cap of 655.71M, Corvus Pharmaceuticals(CRVS) trades at $8.89. The stock has a price-to-earnings ratio of -16.40.
On 2025-11-17, Corvus Pharmaceuticals(CRVS) stock traded between a low of $7.81 and a high of $8.98. Shares are currently priced at $8.89, which is +13.8% above the low and -1.0% below the high.
Corvus Pharmaceuticals(CRVS) shares are trading with a volume of 1.16M, against a daily average of 1.15M.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $9.55 at its peak.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $9.55 at its peak.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.